Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$5.37+0.03 (+0.56%)
Close on Nov 12, 2026Market cap $337.47MP/E –Yield –
Cytosorbents ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cytosorbents's ebitda for the twelve months ending Dec 31, 2025 was -$13.52M. For fiscal 2025 it was -$13.52M. The highest annual figure on record is -$2.81M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.52M | – |
| FY2024 | Dec 31, 2024 | -$15.12M | – |
| FY2023 | Dec 31, 2023 | -$30.49M | – |
| FY2022 | Dec 31, 2022 | -$30.64M | – |
| FY2021 | Dec 31, 2021 | -$22.01M | – |
| FY2020 | Dec 31, 2020 | -$9.71M | – |
| FY2019 | Dec 31, 2019 | -$18.39M | – |
| FY2018 | Dec 31, 2018 | -$15.19M | – |
| FY2017 | Dec 31, 2017 | -$9.62M | – |
| FY2016 | Dec 31, 2016 | -$11.33M | – |
| FY2015 | Dec 31, 2015 | -$9.19M | – |
| FY2014 | Dec 31, 2014 | -$6.83M | – |
| FY2013 | Dec 31, 2013 | -$4.65M | – |
| FY2012 | Dec 31, 2012 | -$3.44M | – |
| FY2011 | Dec 31, 2011 | -$4.40M | – |
| FY2010 | Dec 31, 2010 | -$2.81M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$4.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.33M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.52M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.17M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.26M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.02M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.16M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.63M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.13M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.80M | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.13M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.57M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.35M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.17M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.47M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.26M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.49M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.15M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.57M | – |
| Q2 FY2018 | Jun 30, 2018 | -$4.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.04M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.75M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.29M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.49M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.52M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.10M | – |
See a number that looks wrong?